Baird raised the firm’s price target on Twist Bioscience to $38 from $27 and keeps an Outperform rating on the shares. The firm said management slightly raised 2024 revenue guidance, but Baird senses some conservatism while noting the cmpany has been pleased with its initial Express Genes launch and believes premium pricing and volume leverage should drive gorss margin improvement in FY2H24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TWST:
- Twist Bioscience price target raised to $25 from $19 at JPMorgan
- Twist Bioscience sees Q2 revenue $70M-$71M, consensus $70.09M
- Twist Bioscience raises FY24 revenue view to $288M-$293M from $285M-$290M
- Twist Bioscience reports Q1 EPS (75c), consensus (78c)
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
